Research Article

CD8+DR+ T-Cells and C3 Complement Serum Concentration as Potential Biomarkers in Thrombotic Antiphospholipid Syndrome

Table 1

Clinical characteristics of patients with thrombotic APS and controls.

ParameterThrombotic
APS ( )
aPL positive controls ( )SLE controls ( )Healthy controls ( )P

Age, y, mean (range)50 (29–78)43 (37–59)42 (30–69)48 (30–75)0.17

Sex
 Men (%)28.921.42536.50.87
 Women (%)71.178.67563.5

Risk factors of thrombosis15 (39)000

Thrombotic event
 Stroke7 (18.42%)000
 DVT4 (10.53%)000
 CRVT4 (10.53%)000
 Pulmonary embolism3 (7.89%)000
 Hepatic vein thrombosis1 (2.63%)000
 Thrombophlebitis1 (2.63%)000
 Different combinations of thrombotic events12 (31.58%)000
 Thrombotic events and miscarriage4 (10.53%)000
 Other2 (5.26%)000
Baseline disease
 Lupus like disease04 (28.6%)00
 Sjogren’s syndrome01 (7.1%)00
 Systemic vasculitis01 (7.1%)00
 Rheumatoid arthritis01 (7.1%)00
 Thrombocytopenia9 (23.7%)3 (21.4%)4 (25%)0
 Cutaneous lupus01 (7.1%)00
 UCTD03 (21.4%)00
Clinical and biological markers
 CRP (mg/dL)2.24 ± 6.840.32 ± 0.341.47 ± 2.820.55
 ESR (mm/hour)20.5 ± 24.89.9 ± 9.914.3 ± 8.90.28
 RF (IU/mL)26.4 ± 20.475.4 ± 183.923.4 ± 11.90.42
 SLEDAI index2.3 ± 1.8

CRP: C-reactive protein; CRVT: central retinal vein thrombosis; DVT: deep vein thrombosis; ESR: erythrocyte sedimentation rate; RF: rheumatoid factor; UDCD: undifferentiated connective-tissue disease.